Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Immutep Ltd (IMM.AX)

Immutep Ltd (IMM.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Immutep Ltd 264 George Street Level 33, Australia Square Sydney NSW 2000 AUS

https://www.immutep.com P: +61 283157003 F: +61 285691880

Description:

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Key Statistics

Overview:

Market Capitalization, $K 546,864
Shares Outstanding, K 1,188,835
Annual Sales, $ 0 K
Annual Net Income, $ -39,896 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -3,075 K
% of Institutional Shareholders 17.63%

Growth:

1-Year Return 95.74%
3-Year Return 4.49%
5-Year Return 55.00%

Per-Share Information:

Latest Earnings Date N/A
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 11/05/19

IMM.AX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -42.12%
Return-on-Assets % -38.61%
Profit Margin % 0.00%
Debt/Equity 0.01
Price/Sales N/A
Price/Book 4.73
Book Value/Share 0.10
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar